The global precision medicine market is experiencing rapid growth, with projections indicating it will surpass $22 billion by 2027. India is emerging as a significant player in this field, leveraging its unique advantages to contribute to the industry's development.
Precision biotherapeutics involves medical interventions tailored to a patient's specific genetic or molecular profile, moving away from generalized treatment plans. This approach allows for early diagnosis, personalized treatments, and minimized adverse effects. Key technologies driving this field include:
These technologies mark a shift from managing symptoms to correcting diseases at the molecular level, offering transformative potential for chronic and genetic illnesses.
The precision medicine industry has seen exponential growth, with the market expected to exceed $22 billion by 2027. Key factors driving this expansion include advances in next-generation sequencing (NGS) and gene editing technologies, the rising prevalence of non-communicable diseases (NCDs), and the integration of AI and big data analytics in clinical decision-making.
While the United States, Europe, and China currently lead global innovation, developing economies like India and Brazil are emerging as competitive hubs due to cost advantages, skilled workforces, and growing genomic research infrastructures.
India accounts for nearly 65% of deaths from non-communicable diseases, highlighting the need for advanced diagnostic and therapeutic approaches. The country's diverse genetic landscape presents an ideal testing ground for precision biotherapeutics.
The Department of Biotechnology (DBT) has prioritized precision biotherapeutics as a focus area under its Biotechnology for Economy, Environment, and Employment (BioE3) policy.
Projects like GenomeIndia and IndiGen are establishing reference genomic databases that reflect India's population diversity. These datasets enable the customization of global drug molecules to fit Indian genetic profiles, addressing the common issue of reduced efficacy of foreign-developed drugs among Indian patients.
Despite its potential, India faces challenges such as regulatory gaps, high costs, and limited access to advanced biotherapeutics. Additional challenges include manufacturing bottlenecks and ethical concerns surrounding data privacy. Addressing these gaps is crucial for India to emerge as a trusted global leader in precision healthcare.
India's strengths in cost-effective research, data analytics, and biotechnology talent can be harnessed to localize global therapies at lower costs, expand access to rural populations, and attract international investment in R&D. Collaborations with global institutions and government support, such as the 'Make in India' initiative for Biotech, could establish India as a global hub for precision therapeutics in the next decade.
Kutos : AI Assistant!
